This month the American company Eli Lilly and Co and the Danish manufacturer Novo Nordisk announced similar measures.
French drugmaker Sanofi announced on Thursday that it will cut the price of its most prescribed insulin in the US by 78% starting in January next year, following similar announcements by its business rivals Eli Lilly and Co and Novo Nordisk.
The price of your product, Lantus, will be limited to $35 for patients with private health plans, “underscoring its long-standing commitment to offering affordable prices for medicines,” the company detailed in a announcement.
In addition to Lantus, Sanofi reported that it will reduce 70 % the market price of your rapid-acting insulin, Apidra.
In this way, the pharmaceutical company follows in the footsteps of the American company Eli Lilly and Co that earlier this month announced the reduction of insulin prices by 70%, as did the Danish Novo Nordiskwhich this week also decided to cut the prices of its product by up to 75% next year.
The actions of the three drug manufacturers, which represent about 90% of the market of insulin in the US, come amid criticism and pressure from US legislators on health care companies over the rising costs of this drug.
For his part, the nation’s president, Joe Biden, claimed victory over the pharmaceutical giants by forcing a price cut on such drugs.
“Three of America’s largest insulin manufacturers have agreed to lower their prices following my call to expand to all Americans my $35 monthly limit for seniors (out-of-pocket insulin costs with the Social Security coverage program). run by the Government). Congress, let’s make it law,” wrote the president on his Twitter account.
